Jennifer L. Meagher

University of Michigan–Ann Arbor — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

37h-index4.6kcitations116works9.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(27), Ubiquitin and proteasome pathways(21), Cell death mechanisms and regulation(19), Glycosylation and Glycoproteins Research(13), RNA and protein synthesis mechanisms(11)

Publications116 total

Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers
Journal of Medicinal Chemistry·2025· 11 cited
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders
Journal of Medicinal Chemistry·2025· 8 cited
Functional anatomy of zinc finger antiviral protein complexes
Nature Communications·2024· 10 citedOpen Access
A minimal complex of KHNYN and zinc-finger antiviral protein binds and degrades single-stranded RNA
Proceedings of the National Academy of Sciences·2024· 9 citedOpen Access
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E Activity in Cancer
ACS Medicinal Chemistry Letters·2024· 7 citedOpen Access
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
Journal of Medicinal Chemistry·2024· 16 cited
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E) Activity in Drug-Resistant Melanoma
2024Open Access
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
Journal of Medicinal Chemistry·2024· 17 cited
Design of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E) for Inhibiting Aberrant Cap-Dependent Translation in Cancer
Journal of Medicinal Chemistry·2023· 16 citedOpen Access
Design of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E) for Inhibiting Aberrant Cap-Dependent Translation in Cancer
2023· 3 citedOpen Access
Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Three Supplementary Tables and Supplementary Figures S1-S13 from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
2023Open Access
Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Jeanne A. Stuckey(44), Shaomeng Wang(25), Chao‐Yie Yang(20), Longchuan Bai(18), Donna McEachern(16), Liu Liu(12), Duxin Sun(11), Bo Wen(10), Zaneta Nikolovska‐Coleska(9), Haibin Zhou(8), Mi Wang(8), Renqi Xu(7), Yujun Zhao(7), Krishnapriya Chinnaswamy(7), Su Qiu(7), Angelo Aguilar(6), Jianfeng Lü(5), Sheng Jiang(5), Peter P. Roller(5), Bing Zhou(5)